Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Lancet Diabetes Endocrinol 2025;13:674684
Cagrilintide, the second generation (2020s) Novo Nordisk took the Pramlintide concept and applied the same half-life extension strategy that they used with Semaglutide: Kept the proline substitutions (anti-amyloid) Added a C20 fatty diacid via a -Glu linker to a lysine residue, albumin binding Additionally stabilized the N- and C-terminal positions Result: Cagrilintide with a half-life of 6.6 days (vs 50 minutes for Pramlintide)
caution and monitoring are advised
It is a peptide specifically a pentadecapeptide of 15 amino acids
US$ 1507.50
Sold : Login>>
